This Peptide Combination Reduces Salt by One-Third

CONFECTIONARY

Harleen Singh

7/31/20265 min read

This is an AI generated illustration and does not represent actual product or service.

Salt reduction has been the food industry's most stubborn reformulation problem for two decades. Potassium chloride brings bitterness. Yeast extracts and other umami boosters help but don't fully close the gap. And the newer wave of "salt-enhancing" peptides — short amino acid chains isolated from fermented foods — has mostly been evaluated one peptide at a time, against a single taste receptor.

A new US patent application from Suzhou Aquafarmtory Biotechnology Co., Ltd. (US 2026/0198540 A1) argues that single-peptide, single-receptor thinking is the reason salt-reduction technology has plateaued. Its answer: combine two peptides that each target a different saltiness receptor, and let them work the sodium-perception pathway from two directions at once.

The Receptor Logic

Saltiness isn't sensed through one mechanism. Two receptor systems are implicated in current taste research: ENaC (the epithelial sodium channel, the receptor most directly tied to classic salt taste) and TMC4 (transmembrane channel-like 4, a more recently characterized salt-taste-related receptor). Most salt-enhancing peptide research to date has screened candidates against one of these targets and stopped there.

This patent's central move is combinatorial: it identifies one peptide with strong affinity for TMC4 and a second with strong affinity for ENaC, then combines them in a defined ratio. The hypothesis — and the patent backs it with binding-energy modeling and sensory data — is that hitting both receptor pathways simultaneously produces a synergistic saltiness boost that neither peptide achieves alone.

The two lead peptides are:

EF10 (sequence EDEGEQPRPF) — the stronger TMC4 binder, originally isolated from fermented tofu curd (fermented soybean curd) and characterized in a 2021 peer-reviewed paper
PP9 (sequence PKLLLLPKP) — the stronger ENaC binder, originally isolated from yeast extract and characterized in a 2022 peer-reviewed paper

Both are worth pausing on, because neither is a novel discovery in this patent. Their isolation and initial salt-enhancing activity were independently published by outside academic groups in Journal of Agricultural and Food Chemistry before this application. That's a meaningful credibility signal: the peptides' baseline salt-perception activity isn't just an applicant's internal claim, it's corroborated by prior peer-reviewed characterization work from separate research teams. What Suzhou Aquafarmtory is claiming as new is the specific combination, the ratio, and the mechanistic rationale for why pairing them outperforms either alone.

A third peptide, PQ5 (PHEMQ, isolated from a mushroom species and known primarily for umami rather than saltiness), is tested in some combinations as a comparison and shows the combinatorial logic isn't unlimited — more peptides isn't automatically better, as the data below shows.

How the Case Is Built

The application layers three independent lines of evidence, which is more rigorous than most peptide-ingredient patents attempt:

1. Molecular docking and dynamics. Using Discovery Studio software, the applicant modeled how each peptide binds the 3D structures of TMC4 and ENaC (both derived from public sequence and structure databases), measuring binding energies in kcal/mol. EF10 showed the strongest TMC4 affinity; PP9 showed the strongest ENaC affinity — the structural basis for pairing them.

2. Human sensory panels. A ten-person trained panel (five men, five women) scored saltiness and umami on a 10-point scale across a NaCl-only control, three single-peptide standards, and four peptide-combination samples. The peptide pair matching EF10 (TMC4) with PP9 (ENaC) — Sample 2 — scored highest on both saltiness and umami, and 80% of panelists reported a significant increase in perceived saltiness in a solution containing roughly one-third less salt than the reference standard.

3. Electronic tongue analysis. An instrumental taste sensor (ThinkSenso&Senso platform) was used to cross-check the human panel results, run in ten replicate measurements per sample. The instrumental data tracked the human panel results closely, with the same ranking order — a useful corroboration since electronic tongue data is less subject to panelist variability or expectation bias than a ten-person sensory panel.

It's worth flagging that all three data sets — docking, sensory, and electronic tongue — are applicant-generated for this specific combination, even though the peptides' underlying identities and single-molecule activity were independently published. Readers should treat the synergy claim as this application's own demonstrated result, not yet independently replicated.

The Result That Matters Commercially

The headline number: Sample 2 (EF10 + PP9, ratio 1:1) delivered a NaCl solution with roughly 33% less salt than a reference standard while panelists rated it as saltier, not equal or weaker. If that effect holds up in real food matrices — and solution-based sensory testing is a meaningful step removed from a finished product like a soup base, snack seasoning, or processed meat — it would represent a genuinely useful reduction level. Most commercial sodium-reduction technologies today target 15–25% reduction before flavor compromise becomes noticeable; a 33% reduction with an increase in perceived saltiness would be a stronger result than most published alternatives.

Two things temper that headline, and both are addressed candidly in the patent's own discussion:

More peptides isn't simply better. The three-peptide combination (Sample 4, adding PQ5 to the EF10/PP9 pair) underperformed the two-peptide EF10/PP9 combination. The applicant's own explanation is that PQ5 binds weakly to both receptors and may interfere with the cleaner synergy of the matched pair — a useful negative result that strengthens the credibility of the two-peptide claim rather than undermining it, since it shows the effect isn't just "more peptides, more saltiness."

Testing so far is a simple salt solution, not a food system. Real foods bring fat, protein, starch, and other flavor compounds that routinely blunt or alter peptide-taste interactions. This is standard early-stage work for a taste-modulating ingredient, but it means the reported 33% reduction figure should be read as a proof-of-concept ceiling, not a number food formulators can expect to replicate directly in, say, a bouillon cube or a processed cheese.

Production Route: Precision Fermentation, Not Extraction

Unlike the peptides' original academic discovery — which involved isolating tiny amounts from fermented tofu or yeast extract — Suzhou Aquafarmtory's production method is synthetic biology at fermentation scale. The peptide genes are codon-optimized, synthesized, and expressed in a protease-deficient strain of Pichia pastoris, a yeast widely used in recombinant protein manufacturing (the patent notes it has produced over 5,000 different proteins industrially, including for vaccine production) and already recognized as GRAS by the FDA in other applications.

Using a protease-deficient host strain is a deliberate engineering choice: standard yeast strains carry native proteases that can degrade short synthetic peptides before they're secreted and purified, which is a common yield-killer in peptide bioproduction. Knocking that out is a practical, scale-relevant detail that separates this from a purely academic exercise — it signals the applicant has already thought about manufacturability, not just proof of concept.

Downstream purification uses a fairly conventional ceramic membrane ultrafiltration/nanofiltration sequence, finishing with freeze-drying to a stable powder — standard, scalable unit operations rather than anything exotic.

Where This Fits Competitively

Salt-reduction peptides sit in a crowded and still-nascent ingredient category alongside potassium-based salt substitutes, yeast-derived umami peptides (several already commercialized), and amino acid-based flavor modulators. What differentiates this filing from most is the explicit two-receptor targeting strategy backed by structural modeling — most commercial salt-enhancer peptides on the market today were discovered empirically (screened by taste) rather than designed around known receptor biology.

Bottom Line

This is a well-constructed piece of ingredient science: it starts from published, independently verified peptide biology, adds a genuinely testable mechanistic hypothesis (dual-receptor targeting beats single-receptor targeting), and backs it with three complementary evidence types rather than one. The 33% salt reduction with increased perceived saltiness is a strong result if it holds — but it's currently demonstrated in simple salt solutions with a ten-person panel, not in a finished food matrix. For ingredient buyers and R&D teams tracking the sodium-reduction space, the peptide-combination logic here is worth watching regardless of how this particular filing fares in prosecution — pairing actives against distinct taste receptors, rather than optimizing one molecule in isolation, looks like a genuinely useful direction for the next generation of salt-reduction technology.